Antiangiogenic and antitumoral therapy delivered by a dual-expression L. monocyto

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$210,739.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA137915-01A1
Award Id:
93516
Agency Tracking Number:
CA137915
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
675 Highway one, North Brunswick, NJ, 08902
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
140232815
Principal Investigator:
PAULO MACIAG
(609) 356-8307
PAULO.MACIAG@BMS.COM
Business Contact:
() -
wallecha@advaxis.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Breast cancer is the second most common type of cancer in females, causing over 40,000 deaths in the United States annually. Recently, cancer vaccines have arisen as a potential therapy and several target antigens have been identified in Breast cancer, including Her2/neu antigen. The goal of cancer vaccines is to generate effector T cells that are able to infiltrate and kill the tumor cells. We propose to generate a single recombinant Listeria monocytogenes capable of ta rgeting cancer cells and tumor vasculature by concomitant expression of Her2 and HMW-MAA, which is expressed in pericytes and plays a role in tumor angiogenesis. To address this challenge, a dual-expression Lm platform is created by expressing Her2 from th e chromosome and HMW-MAA from a plasmid. To enhance immunogenicity, both antigens are fused to the virulence factor listeriolysin-O and immune responses and therapeutic efficacy of the dual-expression system will be evaluated, including analysis of tumor-i nfiltrating lymphocytes and tumor vasculature. Delivery of an anti-angiogenic antigen simultaneously with a tumor-associated antigen will likely have a synergistic effect in impacting tumor growth by targeting blood vessels, which might enhance effector T cell infiltration in the tumor and improve the vaccine therapeutic efficacy, besides creating a flexible platform for future use. PUBLIC HEALTH RELEVANCE: Breast cancer is a major health problem in female population, causing the death of over 40,000 Ameri can men annually. In this SBIR Phase I project, Advaxis Inc. will construct a novel, clinically suitable recombinant Listeria monocytogenes capable of targeting Her2 expressing breast cancer cells and tumor vasculature concomitantly, which will be tested i n a mouse tumor model.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government